VXV-01

VXV-01 is a dual-antigen vaccine under development targeting surface antigens of pathogenic fungi, specifically engineered to combat invasive infections caused by Candida species. It is designed as a prophylactic solution to reduce morbidity and mortality in populations at high risk for severe Candida infections, addressing a major unmet medical need given the absence of approved antifungal vaccines for humans. Developed through a collaboration between Appili Therapeutics and Vitalex Biosciences, VXV-01 leverages advanced antigen design to elicit immune responses against Candida surface antigens, aiming for prevention rather than treatment of invasive candidiasis. The vaccine is expected to advance through IND-enabling studies and Phase 1 clinical trials, supported by significant funding from NIAID[4].

Brand names

VXV-01VXV01VXV 01

Other names

VXV-01VXV01VXV 01